Navigation Links
Upsher-Smith Laboratories Announces Expansion of Voluntary Nationwide Recall
Date:2/18/2011

MAPLE GROVE, Minn., Feb. 18, 2011 /PRNewswire/ -- Upsher-Smith Laboratories, Inc., of Maple Grove, Minnesota is voluntarily expanding its previously announced recall of Jantoven® Warfarin Sodium, USP, 3 mg Tablets to include additional products that were packaged on the same packaging line between May 17, 2010 and November 17, 2010.  The company is initiating the recall as a precautionary measure after a single bottle labeled as Jantoven® Warfarin Sodium, USP, 3 mg Tablets was found by a retail pharmacy to contain tablets at a higher, 10 mg strength.

At Upsher-Smith, patient safety is of foremost concern.  The substitution of warfarin, or any other product, may lead to a change in the therapeutic effect of the intended drug.Consistent, continuous dosing of any product is necessary for optimal care for many ill patients.  Patients should check with their health care provider regarding the appropriateness of their current therapy prior to making any change.  

The expanded recall includes the following products:ProductBatch NumberExpiration DateProduct IdentificationAmantadine 100 mg (100-ct bottles)

284166

Aug-12

Peach; imprinted AMT, 832Amantadine 100 mg (100-ct bottles)

280603

Jul-12

Peach; imprinted AMT, 832Amantadine 100 mg (100-ct bottles)

283797

Jul-12

Peach; imprinted AMT, 832Amlodipine 5 mg (90-ct bottles)

280564

May-12

White; scored; imprinted ALP, 5, 832Amlodipine 5 mg (90-ct bottles)

282661

Aug-12

White; scored; imprinted ALP, 5, 832Androxy 10 mg (100-ct bottles)

283336

Sep-12

Green; scored; imprinted 86, 832Baclofen 10 mg (90-ct bottles)

284651

Sep-12

White; scored; imprinted BAC, 10, 832Baclofen 10 mg (90-ct bottles)

282346

Aug-12

White; scored; imprinted BAC, 10, 832Baclofen 10 mg (100-ct bottles)

281664

Aug-12

White; scored; imprinted BAC, 10, 832Bethanechol 5 mg (100-ct bottles)

282255

Aug-12

White; scored; imprinted BCL, 5, 832Bethanechol 10 mg (100-ct bottles)

280569

Jun-12

White; scored; imprinted BCL, 10, 832Bethanechol 25 mg (100-ct bottles)

280567

Jun-12

Yellow; scored; imprinted BCL, 25, 832Jantoven 1 mg (100-ct bottles)

280617

Mar-12

Pink; scored; imprinted WRF, 1, 832Jantoven 1 mg (100-ct bottles)

282872

Jul-12

Pink; scored; imprinted WRF, 1, 832Jantoven 2 mg (100-ct bottles)

280598

Jun-12

Lavender; scored; imprinted WRF, 2, 832Jantoven 2.5 mg (100-ct bottles)

281667

Jul-12

Green; scored; imprinted WRF, 2 ½, 832Jantoven 3 mg (100-ct bottles)

280612

Jun-12

Tan; scored; imprinted WRF, 3, 832Jantoven 3 mg (100-ct bottles)

284081

Sep-12

Tan; scored; imprinted WRF, 3, 832Jantoven 4 mg (100-ct bottles)

283334

Jul-12

Blue; scored; imprinted WRF, 4, 832Jantoven 5 mg (100-ct bottles)

280581

Jun-12

Peach; scored; imprinted WRF, 5, 832Jantoven 5 mg (100-ct bottles)

283340

Jul-12

Peach; scored; imprinted WRF, 5, 832Jantoven 5 mg (100-ct bottles)

283459

Sep-12

Peach; scored; imprinted WRF, 5, 832Jantoven 5 mg (100-ct bottles)

283455

Jun-12

Peach; scored; imprinted WRF, 5, 832Jantoven 6 mg (100-ct bottles)

282277

Jun-12

Teal; scored; imprinted WRF, 6, 832Jantoven 6 mg (100-ct bottles)

284079

Sep-12

Teal; scored; imprinted WRF, 6, 832Jantoven 7.5 mg (100-ct bottles)

280614

Aug-12

Yellow; scored; imprinted WRF, 7 ½,

832Jantoven 10 mg (100-ct bottles)

283342

Aug-12

White; scored; imprinted WRF, 10, 832Jantoven 10 mg (100-ct bottles)

282917

Feb-12

White; scored; imprinted WRF, 10, 832Oxybutynin 5 mg (100-ct bottles)

283368

Jul-13

White; scored; imprinted 38, 832Upsher-Smith Laboratories is working cooperatively with the U.S. Food and Drug Administration to implement a nationwide recall as quickly and efficiently as possible.

The products affected were distributed to wholesalers, retail chains and independent pharmacies throughout the United States. The company is notifying its pharmacy customers and wholesalers, and arranging for the return of all recalled products.  These products were packaged at the Upsher-Smith plant in Plymouth, Minnesota.

Consumers and pharmacists can call 1-877-492-4791 for more information and to access product details, Monday-Friday between 8:00 a.m. and 5:00 p.m. (EST).

Any adverse reactions may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

Online:

www.fda.gov/MedWatch/report.htmRegular:

Use postage-paid, pre addressed Form FDA 3500 available at: www.fda.gov/MedWatch/getforms.htm.  Mail to address on the pre-addressed form.Fax:

1-800-FDA-0178About Upsher-SmithUpsher-Smith Laboratories, Inc., founded in 1919, is a privately held pharmaceutical company that develops, manufactures and markets prescription and over-the-counter products.  Upsher-Smith's product portfolio focuses in the areas of women's health, dermatology, cardiology, and CNS diseases. Upsher-Smith is headquartered in Maple Grove, Minn. For more information, visit www.upsher-smith.com.


'/>"/>
SOURCE Upsher-Smith Laboratories, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Upsher-Smith Introduces Nexa™ Select With More Plant-Based DHA Than Any Other Once-Daily Single Gel Capsule Rx Prenatal Vitamin
2. Upsher-Smith Laboratories Announces Initiation of Open-Label Extension Study of USL255 (Extended-Release Topiramate) for Adjunctive Treatment of Partial-Onset Epilepsy
3. Novo Nordisk Inc. Announces Exclusive Agreement With Upsher-Smith Laboratories, Inc. to Market Vagifem® 10 mcg
4. Upsher-Smith Laboratories Adds ITI-111 (Nasal Midazolam) to CNS Development Pipeline
5. Upsher-Smith Laboratories Announces Initiation of Phase III Clinical Trial of USL255 (Extended-Release Topiramate) for Adjunctive Treatment of Partial-Onset Epilepsy
6. Upsher-Smith Introduces New Formulation of PreNexa® Prenatal Vitamins
7. Upsher-Smith Announces New Formulation of PreNexa(R) Prenatal Vitamins
8. Upsher-Smith Announces Milestone in Development of CNS Strategy
9. New Data: Cholesterol Management Analysis of Upsher-Smiths Slo-Niacin(R) Tablets in Combination with Lipitor(R)
10. Announcement - Clontech Laboratories, Inc. Releases the Tet-Express™ Inducible Expression System
11. Reportlinker Adds The U.S. Medical Laboratories Industry - 10th Edition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... Wegener Polyangiitis - Pipeline Review, H2 ... Polyangiitis - Pipeline Review, H2 2015, provides an ... This report provides comprehensive information on the therapeutic ... at various stages, therapeutics assessment by drug target, ... and molecule type, along with latest updates, and ...
(Date:2/4/2016)... Frontier Pharma: Chronic Obstructive Pulmonary Disease ... Chronic Obstructive Pulmonary Disease (COPD) is ... the airways and lungs. Persistent breathing difficulties and ... one of the leading causes of morbidity and ... COPD is linked to cumulative exposure to risk ...
(Date:2/4/2016)... 2016 In response to the opioid abuse epidemic, ... for Medical Products and Tobacco, along with other FDA leaders, ... approach to opioid medications. The plan will focus on policies ... pain access to effective relief. --> ... Re-examine the risk-benefit paradigm for opioids and ensure that the ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... February 05, 2016 , ... Love is in the air at King Kullen! ... assortments and packaging. This staple for Valentine’s Day is a must-have, and can be ... Valentine’s Day, not only are long-stem roses available, but also other flower bouquets, elegantly ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... of Popeyes Louisiana Kitchen restaurants, launched the 14th annual “Appetite for a Cure” ... adults with muscular dystrophy, ALS and related diseases that severely limit strength and ...
(Date:2/5/2016)... , ... February 05, 2016 , ... ... devoted exclusively to funding innovative lymphoma research and serving the lymphoma community through ... poised to once again host, Swirl, A Wine Tasting Event at the La ...
(Date:2/5/2016)... ... February 05, 2016 , ... Give To Cure today announced ... and donate to Give To Cure’s campaign that is crowdfunding clinical trials to help ... and share payments through a smart device. In 2015 alone, Venmo processed $7.5 billion ...
(Date:2/5/2016)... ... 2016 , ... Stuart Bentkover, MD, FACS is thrilled to announce ... most effective tattoo removal today, Dr. Bentkover is the only doctor in Central Massachusetts ... PicoSure has been approved by the Food and Drug Administration (FDA) as a safe ...
Breaking Medicine News(10 mins):